Evaluation of allergenic properties and immunotoxicity tablet dosage form GML-1 (N-benzyl-N-methyl-1-phenylpyrrolo[1,2-a]pyrazin-3-carboxamide)

Evaluation of allergenic properties and immunotoxicity tablet dosage form GML-1 (N-benzyl-N-methyl-1-phenylpyrrolo[1,2-a]pyrazin-3-carboxamide)

Blog Article

The study of allergenic properties and immunotoxic effects of the ready-to-use drug form of GML-1 (N-benzyl-N-methyl-1-phenylpyrrolo[1,2-a] pyrazin-3-carboxamide), compounds with high TSPO affinity and pronounced anxiolytic activity, was carried out.The study of allergenic properties and immunotoxicity of GML-1 was performed on male albino guinea pigs weighing 250-300 g and on male CBA, C57BL / rubbermaid 8 gallon trash can 6, F1 hybrids (CBAxC57BL/6) mice.When assessing immunotoxicity, GML-1 was inject to mice per os for 14 days in doses of 2.

2 mg / kg and 22 mg / kg.When studying the allergenicity, GML-1 was injected to albino guinea pigs in doses of 1 mg / kg and 10 mg / kg according to standard regimens of immunization.The results of the study of the immuno-toxicity and allergenicity of GML-1 allow us to conclude that the injection of tablet dosage form of GML-1 in the range of studied flexcon reverse osmosis water storage tank doses does not have an immunotoxic effect and allergenic properties.